Description  Claims  Drawing  Cited references 

WO2005009389A   [0004] 
WO2005097765A   [0004] 
WO2005080393A   [0004] 
WO2005016894A   [0004] 
WO2008051547A   [0005]  [0036] 

Oncogene   [0001] 
Cancer: Principle and Practise of Oncology   [0002] 
J. Clin. Oncol.   [0002] 
Blood   [0002] 
Brat. J. Haematol.   [0002] 
Nature   [0002] 
Blood   [0002] 
Mol. Cell Biol.   [0002] 
Blood   [0002] 
Exp. Hematol.   [0002] 
Cancer Res.   [0002] 
Clin. Cancer Res   [0002] 
Am. J. Pathol.   [0002] 
J. Biol. Chem   [0003] 
J. Biol. Chem   [0003] 
J. Neurochem.   [0003] 
Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention   [0006] 
Role of focal adhesion kinase in human cancer - a potential target for drug discovery   [0006] 
Focal adhesion kinase: in command and control of cell motility   [0006] 
The role of focal adhesion kinase in cancer - a new therapeutic opportunity   [0006] 
Over expression of the focal adhesion kinase (p125 FAK) in invasive human tumors   [0006] 
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma   [0006] 
Focal adhesion kinase in oral cancers   [0006] 
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy   [0007] 
Therapeutic efficacy of a novel focal adhesion kinase inhibitor, TAE226 in ovarian carcinoma   [0007] 
Anti-tumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271   [0007] 
Dual focal adhesion kinse/Pyk2 inhibitor has positive effects on bone tumors - implications for bone metastases   [0007] 
Remington: The Science and Practice of Pharmacy   [0030] 
Properties, Selection, and Use   [0039] 
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer   [0058]